Why FMC's rimisoxafen herbicide is suddenly on every agronomist’s radar

Reviewed: ad hoc news Software & Services desk. Edited and checked on 2026-06-18, 08:24. Details in the imprint.

Rimisoxafen from FMC enters the stage as the quiet, clear liquid that promises to finally hurt the weeds that stopped caring about older herbicides. Farmers will not see it in shiny retail cans yet, but in premix jugs built for long, dirty days in the sprayer.

What rimisoxafen is meant to do

At its core, rimisoxafen is an experimental herbicide active ingredient designed to tackle tough, resistant weeds in corn and soybean fields, especially in North and South America. FMC describes it as a breakthrough molecule with a dual mode of action targeting key biochemical pathways in weeds.

The company positions the chemistry to protect yield where traditional herbicides are fading, particularly in geographies drowning in glyphosate- and ALS-resistant broadleaf and grass species. In practice, farmers should experience cleaner rows longer into the season, with less pressure to stack multiple overlapping products.

Dual-action punch against resistance

The standout feature is the dual mode of action built into rimisoxafen, which the company presents as the first of its kind in the herbicide industry. By hitting weeds in two different ways within the same molecule, FMC aims to delay resistance buildup that has hamstrung many older modes of action.

This is not simply a tank mix of two actives but a single compound crafted to interact at two target sites, which should help agronomists design more robust herbicide programs. For growers, the benefit is meant to be straightforward: fewer escapes, more predictable fields, and less frustration when scouting after a rain.

Licensing deal with Corteva raises the stakes

Earlier this week FMC and Corteva announced a co-exclusive strategic supply and license agreement that gives Corteva access to rimisoxafen for corn and soybean markets across North and South America. Under the deal, FMC keeps ownership of the active ingredient and supplies it to Corteva, which will formulate its own premix products.

Both companies will independently develop and commercialize exclusive premix formulations, with first commercial sales expected toward the end of the decade, subject to regulatory approvals. Corteva is making an initial prepurchase payment of 200 million US dollars for supply, underscoring how seriously it takes the technology.

How farmers will likely encounter it

Growers will not buy a can labeled simply "rimisoxafen" at the local ag retailer. Instead, they will see branded premix herbicides from FMC and Corteva that pair the new active with established partners tailored to specific weed spectrums and geographies.

The formulations are aimed particularly at corn and soybean rotations in the Americas, where resistant Palmer amaranth, waterhemp and other problem species have forced increasingly complex weed control stacks. If the technology delivers as advertised, spray passes could become more effective rather than just more expensive.

Regulatory path and timing

Rimisoxafen is still moving through the regulatory pipeline, so for now it lives more in stewardship meetings and investor decks than on sprayer rigs. FMC and Corteva both signal that large-scale commercial launches are anticipated by the end of the decade, once registrations are secured in key countries.

The long lead time gives both companies room to build data, refine application recommendations and train dealers before the first jugs ship in volume. For farmers watching resistance worsen each season, however, the wait could feel uncomfortably long.

What this means for FMC Corp

Within FMC’s portfolio, rimisoxafen is one of the flagship technology platforms the company highlights as a future growth engine in crop protection. Management frames the molecule as a way to defend pricing power and margins in an industry that increasingly depends on differentiated, patent-protected chemistry.

Shares of FMC Corp (ISIN US3024913036) trade on the New York Stock Exchange in US dollars.

This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.